potassium citrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4519 866-84-2

Description:

MoleculeDescription

Synonyms:

  • potassium citrate anhydrous
  • potassium citrate
  • tripotassium citrate
A powder that dissolves in water, which is administered orally, and is used as a diuretic, expectorant, systemic alkalizer, and electrolyte replenisher.
  • Molecular weight: 306.39
  • Formula: C6H5K3O7
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 140.62
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
4 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
April 30, 2021 EMA Advicenne S.A.
Aug. 30, 1985 FDA MISSION PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 110.89 19.54 96 3949 201306 63283671
Multiple fractures 71.08 19.54 25 4020 8593 63476384
Hypertonic bladder 60.86 19.54 18 4027 3570 63481407
Haematochezia 57.16 19.54 38 4007 53506 63431471
Therapeutic drug monitoring analysis not performed 47.34 19.54 12 4033 1340 63483637
Nephrolithiasis 42.88 19.54 29 4016 41955 63443022
Fall 38.44 19.54 80 3965 392254 63092723
Systemic infection 36.45 19.54 13 4032 4647 63480330
Product monitoring error 33.07 19.54 12 4033 4504 63480473
Anaemia 32.48 19.54 63 3982 293367 63191610
Dementia 26.70 19.54 16 4029 18778 63466199
Nasal polypectomy 25.15 19.54 4 4041 39 63484938
Dizziness 24.25 19.54 71 3974 429854 63055123
Gait disturbance 23.57 19.54 42 4003 183136 63301841
Product residue present 23.39 19.54 9 4036 3970 63481007
Balance disorder 22.00 19.54 27 4018 84395 63400582
Dehydration 21.35 19.54 39 4006 173315 63311662
Faeces soft 20.28 19.54 9 4036 5683 63479294
Anaemia of malignant disease 19.98 19.54 5 4040 530 63484447

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrolithiasis 64.16 21.78 38 3183 30295 34923415
General physical health deterioration 49.66 21.78 60 3161 128209 34825501
Tracheal pain 29.96 21.78 5 3216 45 34953665
Waist circumference increased 28.59 21.78 8 3213 898 34952812
Regurgitation 27.63 21.78 9 3212 1690 34952020
N-terminal prohormone brain natriuretic peptide increased 27.15 21.78 10 3211 2705 34951005
Vitamin B12 deficiency 26.66 21.78 11 3210 4020 34949690
Consciousness fluctuating 26.46 21.78 8 3213 1179 34952531
Respiratory tract haemorrhage 25.93 21.78 8 3213 1262 34952448
Aortic stenosis 25.83 21.78 11 3210 4347 34949363
Eye swelling 25.05 21.78 14 3207 9981 34943729
Oesophageal ulcer 25.02 21.78 10 3211 3371 34950339
Atrioventricular block 24.97 21.78 13 3208 8050 34945660
Dysuria 24.12 21.78 20 3201 27132 34926578
Oedema peripheral 23.98 21.78 41 3180 119771 34833939
Systemic infection 23.94 21.78 11 3210 5201 34948509
Interstitial granulomatous dermatitis 23.51 21.78 5 3216 177 34953533
Abdominal pain 22.83 21.78 48 3173 163570 34790140
Oropharyngeal discomfort 22.08 21.78 9 3212 3187 34950523
Pain 21.86 21.78 54 3167 204621 34749089

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 164.09 17.37 153 6367 275085 79462783
Nephrolithiasis 78.99 17.37 51 6469 53240 79684628
Multiple fractures 66.71 17.37 25 6495 8001 79729867
Systemic infection 58.55 17.37 24 6496 9728 79728140
Hypertonic bladder 53.63 17.37 18 6502 4183 79733685
Therapeutic drug monitoring analysis not performed 53.45 17.37 15 6505 1921 79735947
Product monitoring error 43.73 17.37 19 6501 8887 79728981
Dehydration 37.16 17.37 70 6450 248117 79489751
Haematochezia 36.03 17.37 40 6480 87605 79650263
Oedema peripheral 35.12 17.37 69 6451 252219 79485649
Anaemia 34.78 17.37 97 6423 444918 79292950
Fall 33.98 17.37 102 6418 487527 79250341
Cardiac failure chronic 33.69 17.37 17 6503 11118 79726750
Dysuria 31.48 17.37 29 6491 50922 79686946
Tracheal pain 30.55 17.37 5 6515 45 79737823
N-terminal prohormone brain natriuretic peptide increased 26.17 17.37 11 6509 4744 79733124
Dizziness 25.91 17.37 98 6422 526343 79211525
Vitamin B12 deficiency 24.71 17.37 12 6508 7229 79730639
Waist circumference increased 24.62 17.37 8 6512 1681 79736187
Localised infection 24.41 17.37 22 6498 37553 79700315
Regurgitation 24.32 17.37 9 6511 2778 79735090
Respiratory tract haemorrhage 24.02 17.37 8 6512 1815 79736053
Interstitial granulomatous dermatitis 22.68 17.37 5 6515 237 79737631
Product residue present 22.24 17.37 9 6511 3527 79734341
Atrioventricular block 22.18 17.37 14 6506 14027 79723841
Nephrocalcinosis 21.43 17.37 7 6513 1495 79736373
Aortic stenosis 21.39 17.37 11 6509 7484 79730384
Consciousness fluctuating 19.57 17.37 7 6513 1962 79735906
Oesophageal ulcer 19.22 17.37 10 6510 6965 79730903
Dementia 19.17 17.37 16 6504 24643 79713225
Pain 19.03 17.37 110 6410 703692 79034176
Chronic kidney disease 18.71 17.37 25 6495 66129 79671739
Renal impairment 18.22 17.37 40 6480 157743 79580125
Pseudoporphyria 17.95 17.37 5 6515 623 79737245
Electrocardiogram abnormal 17.65 17.37 13 6507 16724 79721144

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A12BA02 ALIMENTARY TRACT AND METABOLISM
MINERAL SUPPLEMENTS
POTASSIUM
Potassium
FDA MoA N0000009986 Alkalinizing Activity
FDA EPC N0000175896 Metabolic Alkalinizer
CHEBI has role CHEBI:35498 diuretics
MeSH PA D004232 Diuretics
MeSH PA D005100 Expectorants
MeSH PA D045283 Natriuretic Agents
MeSH PA D019141 Respiratory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal tubular acidosis indication 1776003 DOID:14219
Hypokalemia indication 43339004
Uric acid renal calculus indication 274401005
Calcium renal calculus indication 427649000
Hypokalemia Prevention indication
Calcium Oxalate Renal Calculi indication
Calcium Phosphate Renal Calculi indication
Cystinuria off-label use 85020001 DOID:9266
Cystine Renal Calculi off-label use
Metabolic alkalosis contraindication 1388004
Anuria contraindication 2472002 DOID:2983
Hypocalcemia contraindication 5291005
Peptic ulcer contraindication 13200003 DOID:750
Hyperkalemia contraindication 14140009
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Ventricular tachycardia contraindication 25569003
Complete atrioventricular block contraindication 27885002
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypernatremia contraindication 39355002
Gastrointestinal ulcer contraindication 40845000
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Acidosis contraindication 51387008
Congenital myotonia, autosomal dominant form contraindication 57938005
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Diarrhea contraindication 62315008
Arterial thrombosis contraindication 65198009
Arteriosclerotic vascular disease contraindication 72092001
Hyperchloremia contraindication 74450001
Gastrointestinal hemorrhage contraindication 74474003
Third degree burn injury contraindication 80247002
Oliguria contraindication 83128009
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Myocardial dysfunction contraindication 233928007
Gastroparesis contraindication 235675006
Chronic diarrhea contraindication 236071009
Hyporeninemic hypoaldosteronism contraindication 236464008
Rhabdomyolysis contraindication 240131006
Esophageal dysmotility contraindication 266434009 DOID:9192
Benign prostatic hyperplasia contraindication 266569009
Peripheral edema contraindication 271809000
Familial hyperkalemic periodic paralysis contraindication 304737009 DOID:14451
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Hypoxia contraindication 389086002
Disorder of coronary artery contraindication 414024009
Ketoacidosis in diabetes mellitus contraindication 420422005 DOID:1837
Hypertensive urgency contraindication 443482000
Azotemia contraindication 445009001
Severe dehydration contraindication 450316000
Genitourinary Tract Infections contraindication
Esophageal Compression contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Cattle Dehydration associated with diarrhea Indication
Cattle Early treatment of scouring Indication
Cattle Treatment following intravenous fluid therapy Indication

🐶 Veterinary products

ProductApplicantIngredients
Re-Sorb, Vytrate Zoetis Inc. 6

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D05578 KEGG_DRUG
4017519 VANDF
CHEBI:64733 CHEBI
CHEMBL1200458 ChEMBL_ID
CHEMBL3989822 ChEMBL_ID
DB09125 DRUGBANK_ID
EE90ONI6FF UNII
1374802 RXNORM
35532 MMSL
5328 MMSL
72288 MMSL
NOCODE MMSL
d01423 MMSL
000746 NDDF
000766 NDDF
002330 NDDF
387450001 SNOMEDCT_US
78542000 SNOMEDCT_US
C0137996 UMLSCUI
D019357 MESH_DESCRIPTOR_UI
13344 PUBCHEM_CID
6100-05-6 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Potassium Citrate and Citric Acid HUMAN PRESCRIPTION DRUG LABEL 2 0121-0676 SOLUTION 1100 mg ORAL unapproved drug other 12 sections
Potassium Citrate and Citric Acid HUMAN PRESCRIPTION DRUG LABEL 2 0121-0676 SOLUTION 1100 mg ORAL unapproved drug other 12 sections
TRICITRATES HUMAN PRESCRIPTION DRUG LABEL 3 0121-0677 SOLUTION 550 mg ORAL unapproved drug other 12 sections
TRICITRATES HUMAN PRESCRIPTION DRUG LABEL 3 0121-0677 SOLUTION 550 mg ORAL unapproved drug other 12 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0600 TABLET, EXTENDED RELEASE 5 meq ORAL NDA 22 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0600 TABLET, EXTENDED RELEASE 5 meq ORAL NDA 22 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0600 TABLET, EXTENDED RELEASE 5 meq ORAL NDA 22 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0610 TABLET, EXTENDED RELEASE 10 meq ORAL NDA 22 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0610 TABLET, EXTENDED RELEASE 10 meq ORAL NDA 22 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0610 TABLET, EXTENDED RELEASE 10 meq ORAL NDA 22 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0615 TABLET, EXTENDED RELEASE 15 meq ORAL NDA 22 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0615 TABLET, EXTENDED RELEASE 15 meq ORAL NDA 22 sections
UROCIT-K HUMAN PRESCRIPTION DRUG LABEL 1 0178-0615 TABLET, EXTENDED RELEASE 15 meq ORAL NDA 22 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0245-0070 TABLET 5 meq ORAL NDA 22 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0245-0070 TABLET 5 meq ORAL NDA 22 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0245-0071 TABLET 10 meq ORAL NDA 22 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0245-0071 TABLET 10 meq ORAL NDA 22 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2682 TABLET, EXTENDED RELEASE 5 meq ORAL ANDA 21 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2682 TABLET, EXTENDED RELEASE 5 meq ORAL ANDA 21 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2729 TABLET, EXTENDED RELEASE 10 meq ORAL ANDA 21 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2729 TABLET, EXTENDED RELEASE 10 meq ORAL ANDA 21 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2742 TABLET, EXTENDED RELEASE 15 meq ORAL ANDA 21 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2742 TABLET, EXTENDED RELEASE 15 meq ORAL ANDA 21 sections
TRICITRATES HUMAN PRESCRIPTION DRUG LABEL 3 17856-0677 SOLUTION 550 mg ORAL UNAPPROVED DRUG OTHER 12 sections
POTASSIUM CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-129 TABLET, EXTENDED RELEASE 5 meq ORAL ANDA 16 sections
POTASSIUM CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-130 TABLET, EXTENDED RELEASE 10 meq ORAL ANDA 16 sections
POTASSIUM CITRATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-132 TABLET, EXTENDED RELEASE 15 meq ORAL ANDA 16 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 42291-499 TABLET, EXTENDED RELEASE 10 meq ORAL ANDA 21 sections
Potassium Citrate HUMAN PRESCRIPTION DRUG LABEL 1 42291-500 TABLET, EXTENDED RELEASE 15 meq ORAL ANDA 21 sections
POTASSIUM CITRATEEXTENDED RELEASE HUMAN PRESCRIPTION DRUG LABEL 1 42543-406 TABLET 5 meq ORAL ANDA 20 sections